Gwynedd Valley, PA, United States of America

Andrew M Stern


Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 29(Granted Patents)


Location History:

  • Gwynedd Valley, PA (US) (1990 - 1993)
  • Gwywedd Valley, PA (US) (1993)
  • Lower Gwynedd, PA (US) (2003)

Company Filing History:


Years Active: 1990-2003

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovator Andrew M. Stern: Pioneering Thrombolytic Therapies

Introduction

Andrew M. Stern, based in Gwynedd Valley, PA, is a notable inventor with a focus on advancing medical therapies. With a total of four patents to his name, Stern has made significant contributions to the field of thrombolytic therapy, which is critical for treating blood clots.

Latest Patents

Among Andrew M. Stern's most recent patents is a breakthrough in thrombin receptor antagonists and methods for thrombolytic therapy. His discoveries include certain Factor XIIIa inhibitor compounds that have shown promise in lysing blood clots. These innovations are adaptable for administration either alone or in combination with plasminogen activators, which enhances the effectiveness of thrombolytic treatments.

Career Highlights

Stern's career is marked by his association with Merck & Company, Inc., a leading pharmaceutical company known for its commitment to healthcare innovation. His work at Merck has placed him at the forefront of research and development in thrombolytic therapies, focusing on improvements that can significantly impact patient outcomes.

Collaborations

Throughout his career, Andrew M. Stern has worked alongside esteemed colleagues, including Paul A. Friedman and David A. Claremon. These collaborations have fostered a collaborative environment that promotes innovation and a shared goal of enhancing therapeutic options within the medical field.

Conclusion

With his substantial contributions to thrombolytic therapy, Andrew M. Stern exemplifies the spirit of innovation in medicine. His patents not only highlight his ingenuity but also his commitment to improving healthcare, making a lasting impact on the treatment of blood clot-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…